Učitavanje...
Is autologous transplant in relapsed DLBCL patients achieving only a PET(+) PR appropriate in the CAR T-cell era?
For relapsed chemosensitive diffuse large B-cell lymphoma (DLBCL), consolidation with autologous hematopoietic cell transplantation (auto-HCT) is a standard option. With the approval of anti-CD19 chimeric antigen receptor T cells in 2017, the Center for International Blood and Marrow Transplant Rese...
Spremljeno u:
| Izdano u: | Blood |
|---|---|
| Glavni autori: | , , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
American Society of Hematology
2021
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7955408/ https://ncbi.nlm.nih.gov/pubmed/33120429 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood.2020007939 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|